Pseudotyping pandemics

In this seminar Dr Nigel Temperton will outline the design, development and application of viral pseudotypes and how these are exploited for pandemic preparedness (influenza), and applied to SARS-CoV-2 R&D in the therapeutics and vaccination space.

He will focus on his laboratory's current priority research areas including universal influenza vaccines, pre-pandemic pseudotype libraries and the impact of SARS-CoV-2 variants of concern on vaccine effectiveness.

Speaker

Nigel is a Reader in Molecular Virology at the Medway School of Pharmacy, University of Kent. He is also Director of the Viral Pseudotype Unit.

His research interests lie primarily in emerging/re-emerging and transboundary viruses (SARS-CoV-2, MERS-CoV, SARS-CoV coronavirus, pandemic/inter-pandemic influenza, rabies/lyssaviruses, filovirus) and the methods for their control, in particular by vaccination induced neutralising antibody responses and mAb therapeutics. For this purpose Nigel has established novel virus antibody neutralization assays using harmless “pseudotype” virus mimics for many high-containment viruses (Influenza, coronavirus, rabies, ebola) using repurposed retroviral and lentiviral vector technologies. ORCID: https://orcid.org/0000-0002-7978-3815.

How to attend

This seminar is being held in person in STEM 3.1 (STEM Centre on Square 1, Colchester campus). You can also watch via Zoom (meeting ID: 925 4561 0277)

If you have any queries about this seminar please email Dr Stathis Giotis (e.giotis@essex.ac.uk).